SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir ($PLTR) is trending amid a mixed sentiment, with some traders pointing to a recent report highlighting security flaws in its battlefield communication system while others dismiss it as a hit piece designed to create a buying opportunity. The community is actively debating the company's valuation and future growth prospects in the AI space, with some calling it overvalued and others believing it has significant long-term potential. Despite the debate, some are taking advantage of the dip and loading up on shares, anticipating a rebound.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending after announcing a partnership with Perplexity AI to enhance content discovery and bundle services, sparking community excitement about AI integration. Discussions also revolve around Rumble's ties to cryptocurrency through Tether and potential benefits from a Trump administration. Some traders are eyeing a potential short squeeze given the high short interest.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as users highlight its association with weed culture and its potential for growth, drawing comparisons to Bitcoin. Community members emphasize Weedcoin's focus on freedom, natural growth, and cultural connection, promoting it as more than just a cryptocurrency. Discussions also involve community links and contract addresses.

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

Q/C Technologies Inc.

QCLS is trending as traders discuss its pivot to quantum computing for crypto applications, focusing on the potential of LightSolver's technology. The community is weighing the company's prospects in the quantum and blockchain sectors, drawing comparisons to similar stocks. Some are watching for a potential short squeeze due to its low float and threshold list status.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending due to a recent surge in quantum computing stocks, fueled by a $5.7 million sale of two quantum computers. Community discussions revolve around the stock's high valuation and potential for a short squeeze, with bullish investors targeting higher prices while bears anticipate a significant correction. The broader context involves the rapidly growing quantum computing sector and its speculative nature.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

Alto Neuroscience is trending as traders discuss its potential for a squeeze, with some anticipating a rise to $10 or even $20. This speculation follows news of FDA Fast Track designation for ALTO-101 and investors are actively monitoring chat rooms, hoping for a breakout. The community also discusses the company's financials, pipeline and potential readouts.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc is trending due to Citron Research's positive outlook, sparking significant trading volume and community discussion about a potential short squeeze. Community members are debating the company's long-term prospects, comparing it to other telehealth plays, and speculating on factors such as potential acquisitions and partnerships. Overall, the conversation centers on whether Teladoc is undervalued and poised for a breakout.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending as the community discusses its potential for further gains, with some drawing comparisons to past runs of high-performing stocks. Bullish sentiment is fueled by expectations of filling a price gap and reaching higher price ranges. Some traders are also pointing to defensive rotation into healthcare amid broader market concerns, while others cite the potential impact of tariffs on the healthcare sector.

Epsium Enterprise Ltd. operates as a holding company, which engages in import trading and distribution of wines and spirits. It offers a range of products, including Chinese liquor, French cognac, Scottish whisky, fine wines, champagne, and other miscellaneous alcoholic beverages. Its brands include Moutai, Xijiu, Wuliangye, Remy Martin Cognac, Macallan, Cointreau, Piper Heidsieck Champagne, French Fine Wines, Red and White Wines. The company was founded by Son I Tam on March 24, 2020 and is headquartered in Macau.

Epsium Enterprise Ltd. - Ordinary Shares - Class A

Epsium Enterprise Ltd.

Epsium Enterprise Ltd. ($EPSM) is trending due to a volatile trading pattern, marked by frequent trading halts and significant price swings, reminiscent of other high-flying stocks. Community chatter revolves around whether the stock is a pump-and-dump scheme, with some anticipating a massive sell-off while others hope for continued upward momentum. The stock's connection to the Chinese booze market and its small float are also fueling speculation and trading activity.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum (QBTS) is trending amid general excitement in the quantum computing sector, with community members highlighting its potential for energy-efficient solutions. Some traders are discussing potential breakouts and short squeezes, while others compare QBTS to other quantum and AI stocks. Recent news and government initiatives in quantum tech appear to be driving interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Xenon Pharmaceuticals (XENE) Up 4.2% Since Last Earnings Report?

Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus

XENE's wider Q2 loss highlights its push toward late-stage epilepsy, depression, and bipolar disorder studies with azetukalner.

Biogen shares slipped on Monday after the company said it expects to take a $46 million charge in the second quarter related to R&amp;D deals and milestone payments.&nbsp;The expense is set to shave&nbsp;off about $0.26 off its per-share earnings, both on a GAAP and adjusted basis.The update adds to investor caution following the FDA’s recent signal report published on June 30, which named Biogen’s Alzheimer’s treatment Leqembi as one of several drugs flagged for potential post-marketing safety concerns.&nbsp;The report, compiled from the FDA’s FAERS database, represents a push for increased transparency around adverse event reporting.Analysts at RBC Capital said they do not anticipate major regulatory fallout, noting that the data was already publicly available and the risks broadly acknowledged.&nbsp;However, they said the FDA’s move could still create some sentiment overhang for Biogen and other named firms, including Sarepta, Alkermes, Biohaven, Xenon, and Argenx.<a href="https://stocktwits.com/symbol/BIIB">Biogen’s</a> newly itemized R&amp;D charges follow its Q1 decision to present such costs as a separate line item on its income statement.&nbsp;The company stated that these typically include expenses from licensing deals and asset acquisitions, which are accounted for as in-process research and development.Meanwhile, Biogen is advancing its drug pipeline, beginning a Phase 3 study with felzartamab, which can treat a kidney condition known as primary membranous nephropathy.The trial, dubbed Prominent, began dosing patients late last month and will enroll about 180 adults.On Stocktwits, retail sentiment for Biogen was ‘bullish’ amid ‘low’ message volume.Biogen’s stock has declined 13.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration the logo of Biogen is seen on a smartphone with the FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)  

Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit

The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share.

Equity

Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?

Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus

Deutsche Bank initiates coverage of biopharma stocks, sees 'modest recovery'

Investing.com -- Deutsche Bank initiated coverage on 11 U.S. biopharma stocks in a note Tuesday, assigning Buy ratings to eight companies and Hold ratings to three. 

Earnings Preview: Xenon Pharmaceuticals

Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference

VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will...

Xenon Pharmaceuticals (XENE, $42.15) Stochastic Oscillator left the oversold zone on April 01, 2024

This is a signal that XENE's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)

Xenon Pharmaceuticals Inc. (NASDAQ:XENE  Get Free Report) was the target of some unusual options trading on Wednesday. Stock investors bought 4,063 put options on the stock. This represents an...

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Xenon Pharmaceuticals Inc

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

Current Price	$39.50
Prev Close	$39.20
Open	$39.63
Dividend Yield	0.00%
50-Day Moving Average	$36.38
Beta	0.78
Avg. Volume	725,625.62
PE Ratio	-11.06

52-Week High	$46.00
52-Week Low	$26.74
Market Capitalization	$3.02B
EPS (Annual)	-$3.01
Price to Book	4.76
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

XENE
Xenon Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest XENE News

XENE Xenon Pharmaceuticals Inc